Cargando…

Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare, highly aggressive cancer, often insensitive to conventional chemotherapeutics agents. Early diagnosis, followed by radical surgical resection plus/minus adjuvant mitotane therapy, is nowadays the only valuable option. Unfortunately, one out of four patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fiorentini, Chiara, Grisanti, Salvatore, Cosentini, Deborah, Abate, Andrea, Rossini, Elisa, Berruti, Alfredo, Sigala, Sandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463568/ https://www.ncbi.nlm.nih.gov/pubmed/31057613 http://dx.doi.org/10.1155/2019/6072863

Ejemplares similares

Immunotherapy failure in adrenocortical cancer: where next?
por: Cosentini, Deborah, et al.
Publicado: (2018)

Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen
por: Turla, Antonella, et al.
Publicado: (2022)

Preclinical Evidence of Progesterone as a New Pharmacological Strategy in Human Adrenocortical Carcinoma Cell Lines
por: Tamburello, Mariangela, et al.
Publicado: (2023)

Cytotoxic Effect of Trabectedin In Human Adrenocortical Carcinoma Cell Lines and Primary Cells
por: Abate, Andrea, et al.
Publicado: (2020)

OR12-1 Activity of Abiraterone Acetate in the management of Cushing syndrome associated to advanced adrenocortical carcinoma: results of the ABACUS trial.
por: Abate, Andrea, et al.
Publicado: (2022)

Frequency and outcome of SARS-CoV-2 infection in patients with adrenocortical carcinoma followed at a reference center in Italy
por: Cosentini, Deborah, et al.
Publicado: (2021)

Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient With Metastatic Adrenocortical Carcinoma
por: Cosentini, Deborah, et al.
Publicado: (2021)

THU616 Analysis Of Germline Mutations In Patients With Sporadic Adrenocortical Carcinoma
por: Terzolo, Massimo, et al.
Publicado: (2023)

Different management of adrenocortical carcinoma in children compared to adults: is it time to share guidelines?
por: Grisanti, Salvatore, et al.
Publicado: (2021)

Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer
por: Rossini, Elisa, et al.
Publicado: (2021)

Estrogen-Like Effect of Mitotane Explained by Its Agonist Activity on Estrogen Receptor-α
por: Rossini, Elisa, et al.
Publicado: (2021)

Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy
por: Grisanti, Salvatore, et al.
Publicado: (2021)

Feasibility and Activity of Megestrol Acetate in Addition to Etoposide, Doxorubicin, Cisplatin, and Mitotane as First-Line Therapy in Patients with Metastatic/Unresectable Adrenocortical Carcinoma with Low Performance Status
por: Turla, Antonella, et al.
Publicado: (2023)

A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma
por: Sigala, Sandra, et al.
Publicado: (2022)

Adrenocortical Carcinoma
por: Berruti, Alfredo, et al.
Publicado: (2021)

Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria
por: Ambrosini, Roberta, et al.
Publicado: (2020)

Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience
por: Laganà, Marta, et al.
Publicado: (2020)

Correction: Sigala et al. A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma. Cells 2022, 11, 1439
por: Sigala, Sandra, et al.
Publicado: (2023)

Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study
por: Delbarba, Andrea, et al.
Publicado: (2023)

Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma
por: Laganà, M., et al.
Publicado: (2022)

An update on adrenocortical cell lines of human origin
por: Sigala, Sandra, et al.
Publicado: (2022)

Hyperthermic Intraperitoneal Chemotherapy for Primary or Recurrent Adrenocortical Carcinoma. A Single Center Study
por: Tiberio, Guido Alberto Massimo, et al.
Publicado: (2020)

FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma
por: Tamburello, Mariangela, et al.
Publicado: (2022)

Ovarian Strumal Carcinoid: Case Report, Systematic Literature Review and Pooled Analysis
por: Turla, Antonella, et al.
Publicado: (2022)

Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report
por: di Mauro, Pierluigi, et al.
Publicado: (2023)

Medical Approaches in Adrenocortical Carcinoma
por: Paragliola, Rosa Maria, et al.
Publicado: (2020)

The Role of Immunotherapy in the Treatment of Adrenocortical Carcinoma
por: Karwacka, Izabela, et al.
Publicado: (2021)

Modified GRAS Score for Prognostic Classification of Adrenocortical Carcinoma: An ENSAT Multicentre Study
por: Elhassan, Yasir, et al.
Publicado: (2021)

The Immunotherapy Landscape in Adrenocortical Cancer
por: Pegna, Guillaume J., et al.
Publicado: (2021)

Treatment and outcome of metastatic parathyroid carcinoma: A systematic review and pooled analysis of published cases
por: Alberti, Andrea, et al.
Publicado: (2022)

Sleep disturbances and restless legs syndrome in postmenopausal women with early breast cancer given adjuvant aromatase inhibitor therapy
por: Pedersini, Rebecca, et al.
Publicado: (2022)

Tumor Microenvironment in Adrenocortical Carcinoma: Barrier to Immunotherapy Success?
por: Georgantzoglou, Natalia, et al.
Publicado: (2021)

Microvascular Structural Alterations in Cancer Patients Treated With Antiangiogenic Drugs
por: Coschignano, Maria Antonietta, et al.
Publicado: (2021)

CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells
por: Germano, Antonina, et al.
Publicado: (2018)

Cancer Stemness Associated With Prognosis and the Efficacy of Immunotherapy in Adrenocortical Carcinoma
por: Shi, Xiaoxi, et al.
Publicado: (2021)

Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study
por: Terzolo, Massimo, et al.
Publicado: (2023)

Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study
por: Kimpel, Otilia, et al.
Publicado: (2021)

Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question
por: Caramella, Irene, et al.
Publicado: (2022)

S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study
por: Elhassan, Y S, et al.
Publicado: (2021)

Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer
por: Basile, Vittoria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_522m6rqn5488gel7m22qohcjhs